28 related articles for article (PubMed ID: 38131283)
1. Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial.
Freitas AJA; Nunes CR; Mano MS; Causin RL; Santana IVV; de Oliveira MA; Calfa S; Silveira HCS; de Pádua Souza C; Marques MMC
Sci Rep; 2023 Dec; 13(1):21411. PubMed ID: 38049525
[TBL] [Abstract][Full Text] [Related]
2. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
3. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.
de Pádua Souza C; Carneiro ASB; de Oliveira Lessa AC; Lacerda DC; Paiva CE; Zorzetto MMC; de Freitas AJA; Santana IVV; de Oliveira MA; Palmero EI; Marques MMC; Reinert T
Breast Cancer Res Treat; 2023 Nov; 202(1):57-65. PubMed ID: 37578666
[TBL] [Abstract][Full Text] [Related]
5. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNAs as potential biomarkers in triple-negative breast cancer: a translational research study of the NACATRINE trial.
Aguiar Freitas AJ; Nunes CR; Mano MS; Causin RL; Calfa S; de Oliveira MA; Vidigal Santana IV; Pádua Souza C; Chiquitelli Marques MM
Future Oncol; 2024 Jan; 20(1):25-38. PubMed ID: 38131283
[TBL] [Abstract][Full Text] [Related]
7. An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer.
Tierno D; Grassi G; Zanconati F; Bortul M; Scaggiante B
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675313
[TBL] [Abstract][Full Text] [Related]
8. Role of Platinums in Triple-Negative Breast Cancer.
Lynce F; Nunes R
Curr Oncol Rep; 2021 Mar; 23(5):50. PubMed ID: 33754211
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer.
Ruiz-Manriquez LM; Villarreal-Garza C; Benavides-Aguilar JA; Torres-Copado A; Isidoro-Sánchez J; Estrada-Meza C; Arvizu-Espinosa MG; Paul S; Cuevas-Diaz Duran R
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373139
[TBL] [Abstract][Full Text] [Related]
10. Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer.
Tufano AM; Teplinsky E; Landry CA
Clin Breast Cancer; 2021 Feb; 21(1):1-9. PubMed ID: 32800492
[TBL] [Abstract][Full Text] [Related]
11. Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review.
To NH; Nguyen HQ; Thiolat A; Liu B; Cohen J; Radosevic-Robin N; Belkacemi Y;
Breast Cancer Res Treat; 2022 Jun; 193(2):265-279. PubMed ID: 35397079
[TBL] [Abstract][Full Text] [Related]
12. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis.
Pathak N; Sharma A; Elavarasi A; Sankar J; Deo SVS; Sharma DN; Mathur S; Kumar S; Prasad CP; Kumar A; Batra A
Breast; 2022 Aug; 64():7-18. PubMed ID: 35462344
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
